Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study ...

(PR-inside.com) AURORA, CO / ACCESS Newswire / September 22, 2026 / Rezera Inc. (the "Company"), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, announced plans to launch REVEAL-PAD, a prospective, multi-center observational study to investigate the role of inflammation in peripheral artery disease (PAD) and to identify patients who may be eligible to be screened for the Company's planned Phase 3 trial of ruvonoflast in PAD. "Lengthy enrollment in registrational cardiovascular studies delays answers for the patients who need them. REVEAL-PAD will help us lay the ..